Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : BICO & VITK -- Ignore unavailable to you. Want to Upgrade?

To: JS who wrote (2093)	8/5/1998 9:52:00 AM
From: Frank J. Zecha	Read Replies (1) \| Respond to of 2395

URCE: Biocontrol Technology, Inc. Biocontrol Diasense Subsidiary to Market Diasensor on the Internet PITTSBURGH, Aug. 5 /PRNewswire/ -- Biocontrol Technology, Inc. (Nasdaq: BICO - news) subsidiary Diasense, Inc. today announced marketing plans for the Diasensor(R)1000, the world's first noninvasive glucose sensor, which recently received European marketing approval. Diasense plans to penetrate international markets by aggressive Internet marketing, licensing the Diasensor technology, entering into joint venture agreements to market and/or manufacture the sensor, and by establishing exclusive distributors. Initial focus will be on the 15-member European Union (EU), with a market of 30 million people with diabetes. The Diasensor's market entry price will be US$9,000. In addition, Diasense will proceed with other markets outside the EU with large diabetic populations where the CE Mark is not required but is looked to for medical devices. For example, India, Saudi Arabia, United Arab Emirates, and Pakistan combined account for approximately 26,500,000 diabetics. Because the Diasensor is the first noninvasive glucose sensor to ever be made commercially available to the diabetic population, Diasense will also work to educate and establish a network of clinicians, health care professionals, and diabetic associations in each country. Biocontrol Technology, Inc. (www.bico.com) has its corporate offices in Pittsburgh, PA, and is involved in the development and manufacture of biomedical devices and environmental products. Also located in Pittsburgh, PA, Diasense is a subsidiary of Biocontrol Technology and owns the patent, marketing and distribution rights to the sensor. Biocontrol has the exclusive rights to the research and development and manufacturing of the sensor. This press release contains forward looking statements and shareholders and potential investors are cautioned that such statements are predictions and actual events or results may vary significantly. SOURCE: Biocontrol Technology, Inc. More Quotes and News: Biocontrol Technology Inc (Nasdaq:BICO - news) Related News Categories: internet, medical/pharmaceutical